442 related articles for article (PubMed ID: 16135578)
1. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.
Yonkers KA; Brown C; Pearlstein TB; Foegh M; Sampson-Landers C; Rapkin A
Obstet Gynecol; 2005 Sep; 106(3):492-501. PubMed ID: 16135578
[TBL] [Abstract][Full Text] [Related]
2. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
Pearlstein TB; Bachmann GA; Zacur HA; Yonkers KA
Contraception; 2005 Dec; 72(6):414-21. PubMed ID: 16307962
[TBL] [Abstract][Full Text] [Related]
3. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
4. A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms.
Brown C; Ling F; Wan J
J Reprod Med; 2002 Jan; 47(1):14-22. PubMed ID: 11838304
[TBL] [Abstract][Full Text] [Related]
5. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial.
Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
Obstet Gynecol; 2008 Oct; 112(4):773-81. PubMed ID: 18827119
[TBL] [Abstract][Full Text] [Related]
6. Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24/4 regimen.
Marr J; Niknian M; Shulman LP; Lynen R
Contraception; 2011 Jul; 84(1):81-6. PubMed ID: 21664515
[TBL] [Abstract][Full Text] [Related]
7. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen.
Coffee AL; Kuehl TJ; Willis S; Sulak PJ
Am J Obstet Gynecol; 2006 Nov; 195(5):1311-9. PubMed ID: 16796986
[TBL] [Abstract][Full Text] [Related]
8. Use of an oral contraceptive containing drospirenone in an extended regimen.
Sillem M; Schneidereit R; Heithecker R; Mueck AO
Eur J Contracept Reprod Health Care; 2003 Sep; 8(3):162-9. PubMed ID: 14667328
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone.
Bachmann G; Sulak PJ; Sampson-Landers C; Benda N; Marr J
Contraception; 2004 Sep; 70(3):191-8. PubMed ID: 15325887
[TBL] [Abstract][Full Text] [Related]
10. A prospective randomized trial comparing low-dose ethinyl estradiol and drospirenone 24/4 combined oral contraceptive vs. ethinyl estradiol and drospirenone 21/7 combined oral contraceptive in the treatment of hirsutism.
Oner G; Muderris II
Contraception; 2011 Nov; 84(5):508-11. PubMed ID: 22018126
[TBL] [Abstract][Full Text] [Related]
11. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception.
Borges LE; Andrade RP; Aldrighi JM; Guazelli C; Yazlle ME; Isaia CF; Petracco A; Peixoto FC; Camargos AF
Contraception; 2006 Dec; 74(6):446-50. PubMed ID: 17157100
[TBL] [Abstract][Full Text] [Related]
12. Quality of life issues. Potential role for an oral contraceptive containing ethinyl estradiol and drospirenone.
Dickerson V
J Reprod Med; 2002 Nov; 47(11 Suppl):985-93. PubMed ID: 12497673
[TBL] [Abstract][Full Text] [Related]
13. YAZ and the novel progestin drospirenone.
Mishell DR
J Reprod Med; 2008 Sep; 53(9 Suppl):721-8. PubMed ID: 18980044
[TBL] [Abstract][Full Text] [Related]
14. Oral contraceptives containing drospirenone for premenstrual syndrome.
Lopez LM; Kaptein AA; Helmerhorst FM
Cochrane Database Syst Rev; 2012 Feb; (2):CD006586. PubMed ID: 22336820
[TBL] [Abstract][Full Text] [Related]
15. Ethinyl estradiol 20μg/drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder.
Marr J; Heinemann K; Kunz M; Rapkin A
Int J Gynaecol Obstet; 2011 May; 113(2):103-7. PubMed ID: 21338987
[TBL] [Abstract][Full Text] [Related]
16. Comparison of scales for evaluating premenstrual symptoms in women using oral contraceptives.
Coffee AL; Kuehl TJ; Sulak PJ
Pharmacotherapy; 2008 May; 28(5):576-83. PubMed ID: 18447656
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder.
Freeman EW
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():27-34; discussion 42-3. PubMed ID: 12659404
[TBL] [Abstract][Full Text] [Related]
18. A prospective follow-up of two 21/7 cycles followed by two extended regimen 84/7 cycles with contraceptive pills containing ethinyl estradiol and drospirenone.
Seidman DS; Yeshaya A; Ber A; Amodai I; Feinstein I; Finkel I; Gordon N; Porat N; Samuel D; Shiran-Makler E; Wolman I
Isr Med Assoc J; 2010 Jul; 12(7):400-5. PubMed ID: 20862819
[TBL] [Abstract][Full Text] [Related]
19. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life.
Borenstein J; Yu HT; Wade S; Chiou CF; Rapkin A
J Reprod Med; 2003 Feb; 48(2):79-85. PubMed ID: 12621790
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in the treatment of premenstrual dysphoric disorder: a randomized, double blind placebo-controlled study].
Fu Y; Mi W; Li L; Zhang H; Wang J; Cheng W; Sun L; Li L; Xie S; Zhang J
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):506-9. PubMed ID: 25327732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]